Pharming Group N.V.
Pharming Group to participate in August investor conference
Pharming Group to participate in August investor conference
Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of August:
- Canaccord Genuity 45th Annual Growth Conference, Boston, USA, August 12-13, 2025
Fabrice Chouraqui, Chief Executive Officer, will present on Tuesday, August 12 at 12:00pm EDT/18:00 CEST.
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Canaccord Genuity representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, United Kingdom
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Pandora A/S4.8.2025 13:37:14 CEST | Press release
Transactions in connection with share buyback programme
A.P. Møller - Mærsk A/S4.8.2025 13:23:04 CEST | Press release
Transactions in connection with share buy-back program
A.P. Møller - Mærsk A/S4.8.2025 13:23:04 CEST | Pressemeddelelse
Transaktioner i henhold til aktietilbagekøbsprogram
The Metals Company4.8.2025 13:00:35 CEST | Press release
TMC Releases Two Economic Studies with Combined NPV of $23.6B and Declares World-First Nodule Reserves
Accumulus Synergy4.8.2025 13:00:00 CEST | Press release
Accumulus Synergy Spins Out Accumulus Technologies to Scale Proven Regulatory Platform and Accelerate Global Access to Therapies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom